PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $3,193,000 | -48.6% | 103,996 | +12.3% | 0.00% | -50.0% |
| Q3 2016 | $6,208,000 | +127.7% | 92,595 | +1.2% | 0.01% | +166.7% |
| Q2 2016 | $2,726,000 | +873.6% | 91,504 | +859.1% | 0.00% | – |
| Q1 2016 | $280,000 | -70.7% | 9,541 | -21.6% | 0.00% | -100.0% |
| Q4 2015 | $955,000 | -15.9% | 12,175 | -19.2% | 0.00% | -50.0% |
| Q3 2015 | $1,136,000 | -62.8% | 15,074 | -42.4% | 0.00% | -50.0% |
| Q2 2015 | $3,055,000 | -83.1% | 26,167 | -65.9% | 0.00% | -83.3% |
| Q1 2015 | $18,092,000 | +27.8% | 76,626 | +2.4% | 0.02% | +26.3% |
| Q4 2014 | $14,156,000 | -22.2% | 74,794 | -1.9% | 0.02% | -24.0% |
| Q3 2014 | $18,198,000 | +255.2% | 76,278 | -1.7% | 0.02% | +257.1% |
| Q2 2014 | $5,124,000 | -23.4% | 77,634 | +20.9% | 0.01% | -30.0% |
| Q1 2014 | $6,688,000 | +6.2% | 64,220 | +5.5% | 0.01% | +11.1% |
| Q4 2013 | $6,300,000 | +88.2% | 60,856 | -2.5% | 0.01% | +50.0% |
| Q3 2013 | $3,348,000 | +29.6% | 62,402 | +7.1% | 0.01% | +20.0% |
| Q2 2013 | $2,584,000 | – | 58,238 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |